PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data

Foghorn Therapeutics cuts 40% of staff after Eli Lilly ends a cancer collaboration due to poor data.

9sources
10articles
8velocity
+168%since first seen
46d agofirst detected

🌍 Cross-language spread

PULSE detected this story across 2 language editions of the world's news.

🇬🇧 English Oct 2, 12:00 UTC
🇫🇷 French Oct 3, 07:53 UTC · Orange Actualités

Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

📍 How it ended

Foghorn Therapeutics laid off 40% of its employees after Eli Lilly ended a cancer collaboration due to poor data. The program halt led to stock price target cuts and a rating downgrade to hold by TD Cowen.

The story quieted without a definitive conclusion in the coverage.

Epilogue added 44d ago, after coverage quieted.

The brief

Recent coverage details significant operational and financial contractions at Foghorn Therapeutics, highlighted by a substantial reduction in workforce affecting forty percent of employees. According to reporting from outlets including Barron's, Fierce Biotech, and qz.com, the layoffs coincide directly with the collapse of a cancer collaboration involving Eli Lilly. Additional reports from Investing.com, Seeking Alpha, and GuruFocus note that Eli Lilly ended the deal following poor data from a cancer program, specifically halting the FHD-909 program as indicated in a company update provided via GlobeNewswire. Financial institutions and market analysts have responded swiftly to the development, adjusting ratings and stock price targets across the board.

Coverage from TradingView shows that Guggenheim maintained a Buy rating with a five dollar price target, while H.C. Wainwright cut its stock price target to five dollars due to the program halt, as reported by Investing.com. Furthermore, TD Cowen downgraded Foghorn Therapeutics, changing its stock rating from a previous position to a Hold, specifically citing the trial halt and the Lilly exit in coverage tracked by Seeking Alpha and GuruFocus. The broader market context emphasizes intense trader focus on the company's financial health, cash runway, and technical charts, as detailed by StocksToTrade.

The sudden termination of the major pharmaceutical partnership removes a primary catalyst and funding source for Foghorn Therapeutics, putting immediate pressure on the firm's remaining strategic priorities and operational capacity. Coverage does not yet specify the exact timeline for the workforce reduction execution or the full financial impact of the partnership dissolution beyond the stated program halt and strategic updates. As the situation develops, market observers and stakeholders are tracking how the company manages its remaining cash runway and pivots its strategic priorities following the FHD-909 halt. Coverage from GlobeNewswire indicates that Foghorn Therapeutics has provided updates on these strategic shifts, but further details regarding pipeline adjustments or potential new partnerships remain to be seen in subsequent reporting from financial and biotech news sources.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 44d ago.

Quick answers

Why did Foghorn Therapeutics lay off 40% of its employees?

Coverage states the layoffs follow the collapse of its cancer collaboration with Eli Lilly over poor data and the halting of the FHD-909 program.

How have financial analysts reacted to the news?

TD Cowen downgraded the stock to Hold, H.C. Wainwright cut its price target to five dollars, and Guggenheim maintained a Buy rating with a five dollar price target.

Which outlets have covered the trend?

Outlets include Barron's, Fierce Biotech, qz.com, Investing.com, Seeking Alpha, GuruFocus, TradingView, StocksToTrade, and GlobeNewswire.

Coverage (10)

Topics

Related trends

\n \n \n \n \n \n \n